Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 7Head & Neck 4Tumor-Agnostic 2Dermatologic 2Other solid neoplasm 1Gynecologic 1Genitourinary 1Gastrointestinal 1CNS 1Breast 1

Conditions

Melanoma 2Head and Neck Neoplasms 1

Interventions

Nivolumab 168Ipilimumab 152pembrolizumab 143Cyclophosphamide 126Interleukin-2 70aldesleukin 69fludarabine phosphate 68Radiotherapy 67Biopsy 53Temozolomide 48Blood Specimen Collection 45Peripheral Blood Stem Cell Transplantation 44fludarabine 43Radiosurgery 40trametinib 38Vemurafenib 36dabrafenib 33sargramostim 32Bevacizumab 31Aminolevulinic Acid 31Magnetic Resonance Spectroscopy 30Mycophenolic Acid 29Whole-Body Irradiation 27Specimen Handling 27Photochemotherapy 26Imiquimod 26CTLA-4 Antigen 26Busulfan 26Tacrolimus 25Surveys and Questionnaires 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Tiragolumab × Dermatologic × Clear all
NCT05483400 2025-03-30

TIRACAN

University Medical Center Groningen

Phase 2 Recruiting
97 enrolled
DermatologicHead & Neck

Head and Neck Neoplasms, Melanoma

NCT05060003 2024-02-20

Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection

Washington University School of Medicine

Phase 2 Terminated
7 enrolled 4 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡